Rapa Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$1M
- Investors
-
2
Rapa Therapeutics General Information
Description
Developer of cell therapies designed to treat cancer and autoimmune diseases. The company focuses on commercializing innovative adoptive T cell immunotherapy products that reprogram and harness the power of the immune system for safe, cost-effective, and curative T cell therapies, helping healthcare professionals to cure their diseases with medical technology.
Contact Information
Website
www.rapatherapeutics.comCorporate Office
- 12712 Rock Creek Mill Road
- Suite 5B
- Rockville, MD 20852
- United States
Corporate Office
- 12712 Rock Creek Mill Road
- Suite 5B
- Rockville, MD 20852
- United States
Rapa Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 25-May-2023 | $1M | Completed | Startup | ||
| 1. Seed Round | 01-Oct-2021 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Rapa Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rapa Therapeutics Patents
Rapa Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4150059-A1 | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same | Pending | 13-May-2020 | ||
| EP-4150059-A4 | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same | Pending | 13-May-2020 | ||
| US-12680074-B2 | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same | Active | 13-May-2020 | ||
| US-20230159893-A1 | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same | Active | 13-May-2020 | ||
| US-20260337567-A1 | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same | Pending | 13-May-2020 | C12N5/0636 |
Rapa Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| TEDCO | Venture Capital | Minority | ||
| ArgyleRoad | PE/Buyout | Minority |
Rapa Therapeutics FAQs
-
When was Rapa Therapeutics founded?
Rapa Therapeutics was founded in 2018.
-
Where is Rapa Therapeutics headquartered?
Rapa Therapeutics is headquartered in Rockville, MD.
-
What industry is Rapa Therapeutics in?
Rapa Therapeutics’s primary industry is Drug Discovery.
-
Is Rapa Therapeutics a private or public company?
Rapa Therapeutics is a Private company.
-
What is Rapa Therapeutics’s current revenue?
The current revenue for Rapa Therapeutics is .
-
How much funding has Rapa Therapeutics raised over time?
Rapa Therapeutics has raised $1M.
-
Who are Rapa Therapeutics’s investors?
TEDCO and ArgyleRoad have invested in Rapa Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
